MX340718B - Proceso y sistema para obtener neurotoxina botulinica. - Google Patents

Proceso y sistema para obtener neurotoxina botulinica.

Info

Publication number
MX340718B
MX340718B MX2014008854A MX2014008854A MX340718B MX 340718 B MX340718 B MX 340718B MX 2014008854 A MX2014008854 A MX 2014008854A MX 2014008854 A MX2014008854 A MX 2014008854A MX 340718 B MX340718 B MX 340718B
Authority
MX
Mexico
Prior art keywords
botulinum neurotoxin
obtaining
obtaining botulinum
therapeutic
research
Prior art date
Application number
MX2014008854A
Other languages
English (en)
Inventor
L Ton Jennifer
A Patel Hemant
C Bates Ronald
M Ahmad Wajdie
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340718(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX340718B publication Critical patent/MX340718B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un sistema cromatográfico sustancialmente libre de producto animal (APF) para obtener una neurotoxina botulínica biológicamente activa, caracterizada porque comprende: un primer aparato para cultivar la bacteria Clostridium botulinum, el primer aparato es capaz de contener un medio de cultivo sustancialmente APF; un segundo aparato para fermentar bacteria Clostridium botulinum, la cual ha sido cultivada en el primer aparato, el segundo aparato es capaz de contener un medio de fermentación sustancialmente APF; un tercer aparato para recolectar el medio de fermentación; un cuarto aparato para concentrar el medio de fermentación cosechado y diluir el medio de fermentación filtrado; un quinto aparato para llevar a cabo una primera purificación de la neurotoxina botulínica del medio cosechado en donde el quinto aparato comprende un medio de cromatografía de intercambio aniónico, por lo que se obtiene una primera neurotoxina botulínica purificada; y un sexto aparato para llevar a cabo una segundo purificación dela primera neurotoxina botulínica purificada en donde el sexto aparato comprende un medio de cromatografía de intercambio catiónico por lo que se obtiene una segunda neurotoxina botulínica purificada, en donde la neurotoxina boltulínica obtenida tiene una potencia de por lo menos aproximadamente 2.0 veces 107 unidades/mg de la neurotoxina botulínica, la neurotoxina botulínica obtenida comprende 1 ng o menos de 1 ng de ácido nucleico residual por cada mg de neurotoxina botulínica obtenida y el proceso se lleva a cabo en una semana o menos.
MX2014008854A 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica. MX340718B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/502,181 US8129139B2 (en) 2009-07-13 2009-07-13 Process for obtaining botulinum neurotoxin
PCT/US2010/041745 WO2011008713A1 (en) 2009-07-13 2010-07-12 Process and system for obtaining botulinum neurotoxin

Publications (1)

Publication Number Publication Date
MX340718B true MX340718B (es) 2016-07-22

Family

ID=42537891

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2012000615A MX2012000615A (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.
MX2016009206A MX375629B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulínica.
MX2014008854A MX340718B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.
MX2020009978A MX2020009978A (es) 2009-07-13 2012-01-12 Proceso y sistema para obtener neurotoxina botulinica.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012000615A MX2012000615A (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.
MX2016009206A MX375629B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulínica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009978A MX2020009978A (es) 2009-07-13 2012-01-12 Proceso y sistema para obtener neurotoxina botulinica.

Country Status (18)

Country Link
US (19) US8129139B2 (es)
EP (5) EP3640259A1 (es)
JP (6) JP5887268B2 (es)
KR (5) KR101916139B1 (es)
CN (2) CN106117325B (es)
BR (1) BR112012000784A2 (es)
CA (1) CA2767760C (es)
CY (2) CY1119519T1 (es)
DK (2) DK3252070T3 (es)
ES (2) ES2770031T3 (es)
HU (2) HUE033888T2 (es)
IN (1) IN2012DN00456A (es)
MX (4) MX2012000615A (es)
PL (2) PL3252070T3 (es)
PT (2) PT2454275T (es)
RU (1) RU2561459C2 (es)
SI (2) SI2454275T1 (es)
WO (1) WO2011008713A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
MXPA06009853A (es) 2005-03-03 2007-03-29 Allergan Inc Medios para bacteria de clostridium y procesos para obtener una toxina clostridial.
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
MX365496B (es) 2009-10-21 2019-06-05 Revance Therapeutics Inc Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
KR20110046178A (ko) * 2009-10-28 2011-05-04 엘지전자 주식회사 이동 단말기
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
US9605887B2 (en) 2011-07-29 2017-03-28 Hdt Expeditionary Systems, Inc. Transportable packaged ice supply system for high temperature environments
GB201113544D0 (en) * 2011-08-05 2011-09-21 Fujifilm Diosynth Biotechnologies Uk Ltd Purification process
WO2014197837A1 (en) * 2013-06-06 2014-12-11 University Of Florida Research Foundation, Inc. Materials and methods for producing a biological toxin
KR102272580B1 (ko) 2013-07-30 2021-07-05 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도
KR101339349B1 (ko) 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
KR20160068972A (ko) * 2013-11-15 2016-06-15 노파르티스 아게 잔여 세포 배양 불순물의 제거
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
KR101729251B1 (ko) 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
WO2017161345A1 (en) 2016-03-18 2017-09-21 Biomadison, Inc. Improved cell based assay
CN117959415A (zh) 2016-09-13 2024-05-03 阿勒根公司 非蛋白质梭菌毒素组合物
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
JP7604222B2 (ja) * 2017-03-22 2024-12-23 ボンチ インコーポレイテッド 治療用のボツリヌス神経毒素
US20210108187A1 (en) * 2017-04-28 2021-04-15 Bonti, Inc. Botulinum neurotoxins production methods
CA3068292A1 (en) * 2017-06-26 2019-01-03 Bonti, Inc. Clostridial neurotoxin formulations and use
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
WO2020129986A1 (ja) 2018-12-21 2020-06-25 一般財団法人阪大微生物病研究会 ボツリヌス毒素の製造方法
KR102197224B1 (ko) 2019-03-29 2020-12-31 (주)제테마 배지 조성물
KR102209159B1 (ko) 2019-03-29 2021-01-29 (주)제테마 독소의 제조방법
KR102516204B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 정제방법
KR102516203B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 제조방법
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR102287437B1 (ko) * 2019-08-14 2021-08-09 주식회사 프로톡스 보툴리눔 독소의 제조방법
TW202136286A (zh) * 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 純化肉毒桿菌毒素的方法
TWI854077B (zh) * 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
KR102724651B1 (ko) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102427362B1 (ko) * 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
KR102850152B1 (ko) * 2022-07-27 2025-08-25 (주)이니바이오 감압건조장치 및 이를 이용한 감압건조방법
EP4615489A1 (en) 2022-11-07 2025-09-17 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
CH720447A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a
WO2025111258A1 (en) * 2023-11-20 2025-05-30 Abbvie Inc. Clostridium botulinum neurotoxin serotype a compositions and improved filtration processes
DE102025101336A1 (de) 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401683A (en) * 1981-07-06 1983-08-30 Fmc Corporation Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
TW257792B (es) * 1992-10-01 1995-09-21 Lilly Co Eli
DE625212T1 (de) 1992-10-13 2000-11-02 Duke University, Durham Verfahren zum entdecken von krankheit von alzheimer.
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
AU2907695A (en) 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
WO1996039167A1 (en) 1995-06-06 1996-12-12 Pearce L Bruce Improved compositions and methods for chemodenervation using neurotoxins
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
WO1998054296A1 (en) 1997-05-28 1998-12-03 Chiron S.P.A. Culture medium with yeast or soy bean extract as aminoacid source and no protein complexes of animal origin
JP4055248B2 (ja) 1998-05-25 2008-03-05 味の素株式会社 精製ヒトアクチビン及びその製造方法
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6558926B1 (en) 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
WO2001036655A2 (en) 1999-11-12 2001-05-25 Eli Lilly And Company Method for optimization of a medium for glycopeptide fermentation
AU1486801A (en) 1999-11-15 2001-05-30 Curagen Corporation Novel growth factor polypeptides and nucleic acids encoding same
DE10004024A1 (de) 2000-01-31 2001-08-02 Guenther Bebenroth Schaltungsanordnung zum Betreiben von Leuchtdioden
ES2275992T5 (es) 2000-02-08 2011-05-18 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
CA2398799C (en) 2000-02-10 2009-04-21 Magna International Inc. Vehicle tailgate with storage capacity
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
DK1419177T3 (da) * 2001-08-14 2008-08-25 Statens Seruminstitut Rensningsproces til fremstilling i stor skala af Gc-globulin og produkt tilvejebragt ved anvendelse af den samt deres anvendelse indenfor medicin
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
KR20030060150A (ko) 2002-01-07 2003-07-16 (주)메디톡스 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
EP1493478B1 (en) * 2003-07-02 2007-04-04 Filtertek Inc. Multiple bridge retainer
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
WO2005072433A2 (en) 2004-01-26 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Toxin induced sympathectomy
WO2005082096A2 (en) 2004-02-24 2005-09-09 Allergan, Inc. Botulinum toxin screening assays
KR100852824B1 (ko) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
US20060069562A1 (en) 2004-09-10 2006-03-30 Adams Marilyn J Word categories
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
WO2006042149A2 (en) 2004-10-06 2006-04-20 Allergan, Inc. Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
US20070277577A1 (en) * 2004-10-29 2007-12-06 Allen Clyde G Sheet metal brake and hinge mechanism therefor
AU2005318106B2 (en) * 2004-12-23 2011-11-03 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a Vitamin K-dependent protein of interest
MXPA06009853A (es) * 2005-03-03 2007-03-29 Allergan Inc Medios para bacteria de clostridium y procesos para obtener una toxina clostridial.
EP1869459B1 (en) 2005-04-05 2010-06-09 Allergan, Inc. Lipophilic dye-based fret assays for clostridial toxin activity
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7744904B1 (en) 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
WO2007059528A2 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
BR122012027456A2 (pt) 2008-03-14 2015-07-14 Allergan Inc Composição farmacêutica compreendendo sorotipo de neurotoxina botulínica a
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
PT3281953T (pt) 2009-03-13 2020-01-15 Allergan Inc Ensaios de base imunológica da actividade de endopeptidase redireccionada
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
MX365496B (es) 2009-10-21 2019-06-05 Revance Therapeutics Inc Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
NL2010545C2 (en) 2013-03-28 2014-09-30 Ihc Holland Ie Bv Skidding system for an offshore installation or vessel.
KR101339349B1 (ko) 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US9889608B2 (en) 2014-11-10 2018-02-13 International Business Machines Corporation Matching the scale of independent objects or intelligently scaling objects when 3D printing
KR101723167B1 (ko) 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101775682B1 (ko) 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법

Also Published As

Publication number Publication date
KR101916139B1 (ko) 2018-11-08
US20220251532A1 (en) 2022-08-11
US11203748B2 (en) 2021-12-21
CN106117325B (zh) 2021-08-10
EP4299070A2 (en) 2024-01-03
CN106117325A (zh) 2016-11-16
JP6704329B2 (ja) 2020-06-03
PL2454275T3 (pl) 2017-12-29
MX375629B (es) 2025-03-06
KR20170019489A (ko) 2017-02-21
KR20120105417A (ko) 2012-09-25
RU2012104778A (ru) 2013-08-20
KR20190111161A (ko) 2019-10-01
US20220033796A1 (en) 2022-02-03
CN102482332B (zh) 2016-08-03
US12241098B2 (en) 2025-03-04
CN102482332A (zh) 2012-05-30
US8357541B2 (en) 2013-01-22
US8324349B2 (en) 2012-12-04
MX2020009978A (es) 2020-10-12
PT3252070T (pt) 2020-01-14
US20120123095A1 (en) 2012-05-17
US20220228136A1 (en) 2022-07-21
JP2024111147A (ja) 2024-08-16
DK2454275T3 (en) 2017-10-23
US20170327811A1 (en) 2017-11-16
HUE033888T2 (en) 2018-01-29
WO2011008713A1 (en) 2011-01-20
EP3252070B1 (en) 2019-10-02
RU2561459C2 (ru) 2015-08-27
US20150184141A1 (en) 2015-07-02
EP4141024A1 (en) 2023-03-01
US20210292727A1 (en) 2021-09-23
KR101784532B1 (ko) 2017-10-11
HUE047362T2 (hu) 2020-04-28
US20120245324A1 (en) 2012-09-27
US20230123158A1 (en) 2023-04-20
IN2012DN00456A (es) 2015-05-15
US11518986B2 (en) 2022-12-06
DK3252070T3 (da) 2020-01-20
US20220145279A1 (en) 2022-05-12
US9719076B2 (en) 2017-08-01
JP5887268B2 (ja) 2016-03-16
KR102344985B1 (ko) 2021-12-31
MX2012000615A (es) 2012-03-26
US11124786B2 (en) 2021-09-21
KR20180122039A (ko) 2018-11-09
JP2020078306A (ja) 2020-05-28
JP6356651B2 (ja) 2018-07-11
EP2454275B1 (en) 2017-07-12
US11530400B2 (en) 2022-12-20
PL3252070T3 (pl) 2020-04-30
ES2770031T3 (es) 2020-06-30
US20120108792A1 (en) 2012-05-03
CA2767760A1 (en) 2011-01-20
EP4299070A3 (en) 2024-03-27
CY1122567T1 (el) 2021-01-27
AU2010273601A1 (en) 2012-02-02
CA2767760C (en) 2018-12-04
EP2454275A1 (en) 2012-05-23
US8927229B2 (en) 2015-01-06
CY1119519T1 (el) 2018-03-07
US8129139B2 (en) 2012-03-06
US10465178B2 (en) 2019-11-05
JP2017070291A (ja) 2017-04-13
US20220204958A1 (en) 2022-06-30
US20110008843A1 (en) 2011-01-13
SI2454275T1 (sl) 2017-12-29
PT2454275T (pt) 2017-10-23
US11326155B2 (en) 2022-05-10
JP2016028601A (ja) 2016-03-03
US20220298496A1 (en) 2022-09-22
US11525130B2 (en) 2022-12-13
HK1247629A1 (en) 2018-09-28
JP2021193103A (ja) 2021-12-23
US20120156756A1 (en) 2012-06-21
KR101667174B1 (ko) 2016-10-17
SI3252070T1 (sl) 2020-03-31
BR112012000784A2 (pt) 2020-08-11
US8932827B2 (en) 2015-01-13
KR20150085140A (ko) 2015-07-22
US20200071686A1 (en) 2020-03-05
EP3640259A1 (en) 2020-04-22
US20230021648A1 (en) 2023-01-26
JP2012532932A (ja) 2012-12-20
US9206409B2 (en) 2015-12-08
EP3252070A1 (en) 2017-12-06
US20230029327A1 (en) 2023-01-26
US20160097045A1 (en) 2016-04-07
ES2643554T3 (es) 2017-11-23

Similar Documents

Publication Publication Date Title
MX2020009978A (es) Proceso y sistema para obtener neurotoxina botulinica.
PH12012500549A1 (en) Methods and systems for purifying non-complexed botulinum neurotoxin
MX2017007641A (es) Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
EP3723596A4 (en) PHYSIOLOGICAL SIGNAL ANALYSIS METHOD, MODULE AND SYSTEM
MX2020001823A (es) Fabricacion continua integrada de principios activos proteinicos terapeuticos.
Hanrieder et al. Spatial neuroproteomics using imaging mass spectrometry
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
MX2009013194A (es) Proteinas de fusion del receptor para productos finales de glicacion avanzada.
PH12014501039B1 (en) Cytotoxic peptides and antibody drug conjugates thereof
MX387280B (es) Sistema para la producción dirigida de una proteína terapéutica dentro de una célula objetivo y uso del sistema.
EP4524972A3 (en) Analysis of genetic variants
MX368177B (es) Proceso continuo de múltiples etapas para purificar anticuerpos.
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
MX378747B (es) Complejos de proteínas de citomegalovirus.
MX369726B (es) Polipéptidos con actividad proteasa.
MX368142B (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
MX379136B (es) Proteinas agonistas receptoras cd40 de cadena sencilla.
EP4306174A3 (en) Composition for controlled ovarian stimulation
DK2027266T3 (da) Multimer til immunstilmulering
EP2596122A4 (en) MODULATORS OF SIRT5 AND TESTS FOR SCREENING
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
PH12017500047A1 (en) Dual cistronic bacterial expression system
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.